Drugs / rFVIII
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02586012 | Sep 2015 → Jan 2020 | hemophilia | Craig Seaman | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT01405742 | Jul 2012 → Nov 2013 | severe hemophilia A | University of Pittsburgh | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03879135 Background | Apr 2019 → Jan 2025 | von Willebrand disease (hereditary or acquired) | Baxalta now part of Shire | Completed | Met primary |
Press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rFVIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02586012 ↗ |
| Known as | recombinant factor VIII | “recombinant factor VIII” NCT01405742 ↗ |
| Action | Restore | “Bleeding is prevented and/or treated with recombinant factor VIII (rFVIII)” NCT02586012 ↗ |
| Modality | Protein / enzyme biologic | “40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks.” NCT01405742 ↗ |
| Route | Intravenous | “by intravenous injection” NCT01405742 ↗ |